Anika Therapeutics | ANIK - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Abbott USD 10.46B 1.15B 2026-06
Agenus USD -199.08M 22.15M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 526.79M 20.55M 2026-06
Integra LifeSciences USD 1.04B 971K 2026-06
Intrexon USD 61.56M 26.1M 2024-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merit Medical Systems USD 358.44M 20.72M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.92B 607M 2026-06
Smith & Nephew USD 2.59B 71M 2026-06
Stryker USD 4.8B 118M 2026-06
Veracyte USD 126.36M 6.37M 2026-06
Xencor USD 87.82M 5.44M 2026-06
Zimmer Biomet Holdings USD 1.83B 140.7M 2026-06